Korro Bio, Inc. (KRRO) Soars 17.6%: Is Further Upside Left in the Stock?
Korro to Present at the 2026 Jefferies Global Healthcare Conference
Korro Selects KRRO-111 as Development Candidate for the Potential Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Reports First Quarter 2026 Financial Results and Provides Corporate Update
Korro to Participate in Upcoming Investor Conferences
What Makes Korro Bio, Inc. (KRRO) a New Buy Stock
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Korro Announces Oral and Poster Presentations at Upcoming Scientific Conferences
Korro Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio, Inc. (KRRO) Reports Q4 Loss, Lags Revenue Estimates
Korro Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Korro Announces Oversubscribed $85 Million Private Placement
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts
Korro to Present at the TD Cowen 46th Annual Health Care Conference
Strength Seen in Korro Bio, Inc. (KRRO): Can Its 13.9% Jump Turn into More Strength?
Korro Bio Analyst Day: KRRO-121 RNA-Editing Candidate Targets Ammonia Control in UCD and HE
Korro Bio, Inc. (KRRO) Analyst/Investor Day Transcript
Korro Bio, Inc. (KRRO) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Korro to Host Virtual Analyst Day on January 27, 2026
Korro Bio (NASDAQ:KRRO) Shares Down 5.9% – Here’s What Happened
Korro to Present at the 44th Annual J.P. Morgan Healthcare Conference
Korro Bio, Inc. (NASDAQ:KRRO) Receives Consensus Rating of “Hold” from Analysts
Korro Bio Early Trial Results Fall Short; Stock Hits New Low
Korro Bio, Inc. (KRRO) Reports Q3 Loss, Lags Revenue Estimates
Korro Reports Third Quarter Financial Results, Provides Updates on KRRO-110 in Alpha-1 Antitrypsin Deficiency and Additional Pipeline Programs
Korro Bio, Inc. (NASDAQ:KRRO) Given Average Recommendation of “Buy” by Brokerages
Korro to Participate in Upcoming Investor and Scientific Conferences
Korro Reports Second Quarter 2025 Financial Results and Provides Business Updates
Korro Receives European Medicines Agency Orphan Drug Designation for KRRO-110
Korro to Participate in Upcoming Investor Conferences
Korro Reports First Quarter 2025 Financial Results and Provides Business Updates
Korro Appoints Biotech Industry Veteran, Loïc Vincent, Ph.D., as Chief Scientific Officer
Korro Reports Full Year 2024 Financial Results and Provides Business Updates
KRRO-110 Receives Orphan Drug Designation from U.S. FDA for Alpha-1 Antitrypsin Deficiency
Korro to Present at the TD Cowen 45th Annual Health Care Conference
Korro to Participate in Upcoming Investor Conferences
Korro Receives Australian HREC Approval and CTN Clearance to Initiate Phase 1/2a Clinical Study (REWRITE) of KRRO-110 for Alpha-1 Antitrypsin Deficiency
Korro to Present at the Jefferies London Healthcare Conference
Korro Announces Regulatory Filing for Initiation of KRRO-110 First-In-Human Study and Formation of Clinical Advisory Board
Korro Bio Is Lagging Wave Life Sciences In RNA Editing. Why It Could Ultimately Lead The Space.
Wall Street Analysts Think Korro Bio, Inc. (KRRO) Could Surge 239.54%: Read This Before Placing a Bet
Korro Announces Oral and Poster Presentations at the 20th Annual Meeting of the Oligonucleotide Therapeutics Society
Korro to Participate in Upcoming September Investor and Scientific Conferences
Korro Reports Second Quarter 2024 Financial Results and Provides Business Updates
Korro to Participate in Upcoming June Investor and Scientific Conferences
Korro Presents Additional Preclinical Data for KRRO-110 at the American Thoracic Society 2024 International Conference
Korro Reports First Quarter 2024 Financial Results and Appointment of Kemi Olugemo, M.D. as Chief Medical Officer